Jane Hook

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Sean Kehoe, Jane Hook, Matthew Nankivell et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Surgery +14

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Neyssa Marina, Sigbjørn Smeland, Stefan Bielack et al. · The Lancet Oncology · 2016 · 541 citations · Full text

Medicine, Oncology, Surgery +14

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

Stefan Bielack, Sigbjørn Smeland, Jeremy Whelan et al. · Journal of Clinical Oncology · 2015 · 421 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

Jeremy Whelan, Stefan Bielack, Neyssa Marina et al. · Annals of Oncology · 2014 · 333 citations · Full text

Medicine, Oncology, Surgery +15

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Andrew R. Clamp, Elizabeth C James, Iain A. McNeish et al. · The Lancet · 2019 · 223 citations · Full text

Medicine, Gynecology, Oncology +14